Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID-19 severe or critically meta-analysis

AlQahtani, 2020
 
NCT04356534
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
20/20 inconclusive
Bajpai M, 2020
 
NCT04346446
RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallyhigh
14/15 inconclusive 254%
PlasmAr, 2020
 
NCT04344535
RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallylow
228/105 inconclusive -6% -17%
PlasmAr, 2020
 
NCT04344535
RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
228/105 inconclusive -6% -17%
Li, 2015
 
ChiCTR2000029757
RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
52/51 inconclusive -37% 36%
Duan, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
10/10 inconclusive -79%
Hegerova, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
20/20 inconclusive -67%
Rasheed, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
21/28 inconclusive -79%
Sean, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
39/156 inconclusive -49%
Joyner, 2020
 
NCT04338360
NRaconvalescent plasma treatmentconvalescent plasma treatmentCOVID-19 severe or criticallyserious
515/561 inconclusive 16%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).